相关实验视频
Updated: Jan 15, 2026

09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
12.6K
芬卡明可以缓解甲基酸诱导的肝纤维化模型
Yonca Yılmaz Ürün1, Gürkan Güner2, Ejder Saylav Bora3
1Department of Gastroenterology, Yüzüncü Yıl University Medical School, Van, Türkiye.
概括
芬卡明通过减少炎症和纤维化,有效地保护大鼠免受甲状腺酸诱导的肝损伤. 这项研究突出了温卡明的作用.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝纤维化是死亡率和发病率的重要原因.
- 甲托雷克萨特 (MTX) 是一种已知诱导肝脏毒性的化疗剂.
- 探索用于肝脏保护的新型治疗剂至关重要.
研究的目的:
- 在大鼠模型中研究温卡明对甲醇酸诱导的肝损伤的肝保护作用.
- 为了评估卡明治疗后肝脏的生物化学和组织病理变化.
主要方法:
- 使用了30只雄性Wistar白色老鼠,其肝脏损伤是由甲醇 (20 mg/kg) 诱导的.
- 鼠被用盐水或胺 (50毫克/公斤/天) 口服治疗了10天.
- 评估了等离子体和肝脏生物标志物,包括加勒-3,细胞激素18,MDA,ALT和TGF-β. 进行了肝脏组织的组织病理学检查.
主要成果:
- 与MTX-盐水组相比,温卡明治疗显著降低了加勒-3,细胞克拉18,MDA和ALT的血水平.
- 芬卡明的使用导致肝脏MDA和TGF-β水平降低.
- 组织病理学分析证实了卡胺对肝损伤的保护作用.
结论:
- 芬卡明显示出显著的肝脏保护性质,可以防止甲醇酸诱导的肝脏毒性.
- 保护机制包括抗氧化,抗炎和抗纤维活性.
- 文卡明可以改善肝功能,由生化和病理学改善证明.
相关概念视频
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
671
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
671
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
808
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
808
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
599
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
599
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456

